Sotorasib was granted accelerated approval from the FDA in May 2021 for KRAS G12C-mutated advanced NSCLC that has progressed on at least one systemic treatment based on the initial result of the CodeBreak 100 trial (10). This evidence concerns the gene KRAS and non-small cell lung carcinoma.